As six-figure price tags become more common, drugmakers are looking for new and innovative payment models to pay for high-cost drugs, The Wall Street Journal reports.
While some have looked to value-based deals as a panacea for a host of issues regarding drug costs, Cigna Chief Clinical Officer Steve Miller tells WSJ it’s “a great lever to pull, but it’s just one more tool in our toolbox.”
“It’s definitely not going to revolutionize the system to make it more affordable,” he said.
To read the full report, click here. (Paid subscription required)